OrthoPediatrics Corp. (NASDAQ: KIDS) and ConforMIS (NASDAQ:CFMS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.
Valuation & Earnings
This table compares OrthoPediatrics Corp. and ConforMIS’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|ConforMIS||$79.90 million||1.96||-$57.58 million||($1.34)||-2.57|
OrthoPediatrics Corp. has higher revenue, but lower earnings than ConforMIS.
This table compares OrthoPediatrics Corp. and ConforMIS’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations and price targets for OrthoPediatrics Corp. and ConforMIS, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
OrthoPediatrics Corp. currently has a consensus target price of $23.67, indicating a potential upside of 17.74%. ConforMIS has a consensus target price of $6.13, indicating a potential upside of 77.54%. Given ConforMIS’s higher possible upside, analysts clearly believe ConforMIS is more favorable than OrthoPediatrics Corp..
Institutional & Insider Ownership
32.8% of ConforMIS shares are owned by institutional investors. 9.6% of ConforMIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
OrthoPediatrics Corp. beats ConforMIS on 5 of the 9 factors compared between the two stocks.
OrthoPediatrics Corp. Company Profile
OrthoPediatrics Corp. is a United States-based medical device company. The Company designs, develops and commercializes orthopedic implants and instruments to meet the specialized needs of pediatric surgeons and their patients. It operates through the OrthoPediatrics segment, which designs, develops and markets implants and devices for children with orthopedic problems. Its products include RESPONSE Spinal Deformity System, PediNail Intramedullary Nail System, PediLoc Plating Systems, ACL Reconstruction System, Locking Cannulated Blade (LCB) plate system, Locking Proximal Femur (LPF) plate system, PediFlex Flexible Nailing System, PediFrag, PediLoc Extension Osteotomy Plate (PLEO), PediLoc Femur Locking Plate System, PediLoc Tibia Locking Plate System, PediPlates system and Spica Table. It markets over 20 surgical systems that serve approximately three categories within pediatric orthopedic market, including trauma and deformity, complex spine and anterior cruciate ligament reconstruct
ConforMIS Company Profile
ConforMIS, Inc. is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints. It offers a line of customized knee implants designed to restore the natural shape of a patient’s knee. It offers iTotal CR, which is a total knee replacement implant. Its iFit technology platform consists of three elements, including iFit Design, its algorithms and computer software that is used to design customized implants and associated single-use patient-specific instrumentation referred to as iJigs, based on computed tomography scans of the patient and to prepare a surgical plan customized for the patient (iView); iFit Printing, which is a three-dimensional printing technology used to manufacture iJigs, and iFit Just-in-Time manufacturing and delivery capabilities.
Receive News & Ratings for OrthoPediatrics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.